+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Arthritic Therapeutic Market Size, Share & Trends Analysis Report By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others), By Product Type, By Regional Outlook and Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 221 Pages
  • March 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5949695
The Global Arthritic Therapeutic Market size is expected to reach $112.6 billion by 2030, rising at a market growth of 5.1% CAGR during the forecast period.

The osteoarthritis segment encompasses a diverse array of treatment modalities, including pharmacological interventions, non-pharmacological therapies, and surgical interventions. Therefore, the osteoarthritis segment captured $7,913.2 million revenue in the market in 2022. Pharmaceutical companies develop and market a range of medications for osteoarthritis, including analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and viscosupplementation agents, to provide symptom relief and improve joint function.



As the prevalence of arthritis continues to rise globally, there is a growing population of individuals affected by the disease. This expanding patient population creates a larger market for arthritis therapies, including pharmacological interventions, non-pharmacological treatments, surgical procedures, and assistive devices, driving demand for arthritis treatments, and supporting market growth. Therefore, the market is expanding significantly due to the growing prevalence of arthritis.

Additionally, complementary and alternative therapies encompass various treatment modalities, including acupuncture, massage therapy, yoga, tai chi, dietary supplements, herbal remedies, and mind-body techniques. Thus, because of the rising focus on complementary and alternative therapies, the market is anticipated to increase significantly.

However, The high cost of arthritis therapeutics places a substantial financial burden on patients, particularly those without adequate insurance coverage or limited financial resources. The financial burden of arthritis management can contribute to medication rationing, skipping doses, or preceding necessary medical interventions, ultimately compromising treatment efficacy and patient outcomes. Thus, high cost can slow down the growth of the market.

The COVID-19 pandemic disrupted routine healthcare services, including outpatient visits, elective procedures, and non-urgent medical appointments, leading to delays in arthritis diagnosis, treatment initiation, and disease monitoring. The COVID-19 pandemic disrupted global drug supply chains, leading to shortages, stockouts, and delays in the availability of certain arthritic medications, including biologic therapies and specialty drugs. Thus, the COVID-19 pandemic had a moderate effect on the market.

By Product Type Analysis

By product type, the market is categorized into non-steroidal anti-inflammatory drugs (NSAIDs), disease modified anti-rheumatoid drugs (DMARDs), biologics, and others. In 2022, the non-steroidal anti-inflammatory drugs (NSAIDs) segment held 38.7% revenue share in the market. NSAIDs are instrumental in managing various symptoms associated with arthritis, including pain, swelling, stiffness, and functional impairment.



By Application Analysis

Based on application, the market is classified into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, and others. The psoriatic arthritis segment acquired 12.9% revenue share in the market in 2022. Psoriatic arthritis represents a significant unmet medical need, as it affects individuals with psoriasis, a common skin condition, and can lead to progressive joint damage, disability, and impaired quality of life if left untreated.

By Regional Analysis

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired 23.4% revenue share in the market. Urbanization and lifestyle changes in the Asia Pacific region, including sedentary lifestyles, unhealthy diets, obesity, and physical inactivity, contribute to the rising prevalence of arthritis.

Recent Strategies Deployed in the Market

  • 2023-Oct: Amgen, Inc. completed the acquisition of Horizon Therapeutics plc, a biopharmaceutical company. Through this acquisition, Horizon will help to further establish Amgen as a leader across a broader range of diseases. Furthermore, the companies will collaborate to serve even more patients worldwide who are suffering from serious illnesses.
  • 2022-Oct: Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company. Through this acquisition, Pfizer enhanced its product portfolio of potential calcitonin gene-related peptide (CGRP) receptor antagonists.
  • 2022-Mar: Pfizer, Inc. completed the acquisition of Arena Pharmaceuticals, Inc., a clinical-stage company. Under this acquisition, Arena Pharmaceuticals will give Pfizer access to a collection of different and promising experimental treatments in areas like stomach and intestine health, skin conditions, and heart-related issues.
  • 2021-Dec: Novartis AG received approval from the US Food and Drug Administration (FDA) for Cosentyx (secukinumab), which is required for the treatment of active enthesitis-related arthritis (ERA) in patients four years and older and active juvenile psoriatic arthritis (JPsA) in patients two years and older. Cosentyx is the first biologic indicated for ERA and the only biologic treatment approved for both ERA and PsA in paediatric patients in the US. The approved paediatric dosing for Cosentyx in children and adolescents is 75 mg (15 kg or more to less than 50 kg) or 150 mg (50 kg or more).
  • 2020-Oct: Merck & Co., Inc. came into an agreement with Novartis AG, a Swiss multinational pharmaceutical corporation. Under this agreement, the M6495, an anti-ADAMTS5 Nanobody intended for potential osteoarthritis (OA) therapy, was introduced. The new product is designed to be administered via self-injection under the skin, with the goal of preserving knee joint structural integrity and alleviating pain.

List of Key Companies Profiled

  • AbbVie, Inc.
  • Pfizer, Inc.
  • Amgen, Inc.
  • Novartis AG
  • F.Hoffmann-La Roche Ltd.
  • Viatris, Inc.
  • Bausch Health Companies, Inc.
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company

Market Report Segmentation

By Application
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Osteoarthritis
  • Ankylosing Spondylitis
  • Others
By Product Type
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Disease Modified Anti-rheumatoid Drugs (DMARDs)
  • Biologics
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Arthritic Therapeutic Market, by Application
1.4.2 Global Arthritic Therapeutic Market, by Product Type
1.4.3 Global Arthritic Therapeutic Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Recent Strategies Deployed in the Arthritic Therapeutic Market
Chapter 5. Global Arthritic Therapeutic Market, by Application
5.1 Global Rheumatoid Arthritis Market, by Region
5.2 Global Psoriatic Arthritis Market, by Region
5.3 Global Osteoarthritis Market, by Region
5.4 Global Ankylosing Spondylitis Market, by Region
5.5 Global Others Market, by Region
Chapter 6. Global Arthritic Therapeutic Market, by Product Type
6.1 Global Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Region
6.2 Global Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Region
6.3 Global Biologics Market, by Region
6.4 Global Others Market, by Region
Chapter 7. Global Arthritic Therapeutic Market, by Region
7.1 North America Arthritic Therapeutic Market
7.1.1 North America Arthritic Therapeutic Market, by Application
7.1.1.1 North America Rheumatoid Arthritis Market, by Country
7.1.1.2 North America Psoriatic Arthritis Market, by Country
7.1.1.3 North America Osteoarthritis Market, by Country
7.1.1.4 North America Ankylosing Spondylitis Market, by Country
7.1.1.5 North America Others Market, by Country
7.1.2 North America Arthritic Therapeutic Market, by Product Type
7.1.2.1 North America Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
7.1.2.2 North America Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
7.1.2.3 North America Biologics Market, by Country
7.1.2.4 North America Others Market, by Country
7.1.3 North America Arthritic Therapeutic Market, by Country
7.1.3.1 US Arthritic Therapeutic Market
7.1.3.1.1 US Arthritic Therapeutic Market, by Application
7.1.3.1.2 US Arthritic Therapeutic Market, by Product Type
7.1.3.2 Canada Arthritic Therapeutic Market
7.1.3.2.1 Canada Arthritic Therapeutic Market, by Application
7.1.3.2.2 Canada Arthritic Therapeutic Market, by Product Type
7.1.3.3 Mexico Arthritic Therapeutic Market
7.1.3.3.1 Mexico Arthritic Therapeutic Market, by Application
7.1.3.3.2 Mexico Arthritic Therapeutic Market, by Product Type
7.1.3.4 Rest of North America Arthritic Therapeutic Market
7.1.3.4.1 Rest of North America Arthritic Therapeutic Market, by Application
7.1.3.4.2 Rest of North America Arthritic Therapeutic Market, by Product Type
7.2 Europe Arthritic Therapeutic Market
7.2.1 Europe Arthritic Therapeutic Market, by Application
7.2.1.1 Europe Rheumatoid Arthritis Market, by Country
7.2.1.2 Europe Psoriatic Arthritis Market, by Country
7.2.1.3 Europe Osteoarthritis Market, by Country
7.2.1.4 Europe Ankylosing Spondylitis Market, by Country
7.2.1.5 Europe Others Market, by Country
7.2.2 Europe Arthritic Therapeutic Market, by Product Type
7.2.2.1 Europe Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
7.2.2.2 Europe Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
7.2.2.3 Europe Biologics Market, by Country
7.2.2.4 Europe Others Market, by Country
7.2.3 Europe Arthritic Therapeutic Market, by Country
7.2.3.1 Germany Arthritic Therapeutic Market
7.2.3.1.1 Germany Arthritic Therapeutic Market, by Application
7.2.3.1.2 Germany Arthritic Therapeutic Market, by Product Type
7.2.3.2 UK Arthritic Therapeutic Market
7.2.3.2.1 UK Arthritic Therapeutic Market, by Application
7.2.3.2.2 UK Arthritic Therapeutic Market, by Product Type
7.2.3.3 France Arthritic Therapeutic Market
7.2.3.3.1 France Arthritic Therapeutic Market, by Application
7.2.3.3.2 France Arthritic Therapeutic Market, by Product Type
7.2.3.4 Russia Arthritic Therapeutic Market
7.2.3.4.1 Russia Arthritic Therapeutic Market, by Application
7.2.3.4.2 Russia Arthritic Therapeutic Market, by Product Type
7.2.3.5 Spain Arthritic Therapeutic Market
7.2.3.5.1 Spain Arthritic Therapeutic Market, by Application
7.2.3.5.2 Spain Arthritic Therapeutic Market, by Product Type
7.2.3.6 Italy Arthritic Therapeutic Market
7.2.3.6.1 Italy Arthritic Therapeutic Market, by Application
7.2.3.6.2 Italy Arthritic Therapeutic Market, by Product Type
7.2.3.7 Rest of Europe Arthritic Therapeutic Market
7.2.3.7.1 Rest of Europe Arthritic Therapeutic Market, by Application
7.2.3.7.2 Rest of Europe Arthritic Therapeutic Market, by Product Type
7.3 Asia Pacific Arthritic Therapeutic Market
7.3.1 Asia Pacific Arthritic Therapeutic Market, by Application
7.3.1.1 Asia Pacific Rheumatoid Arthritis Market, by Country
7.3.1.2 Asia Pacific Psoriatic Arthritis Market, by Country
7.3.1.3 Asia Pacific Osteoarthritis Market, by Country
7.3.1.4 Asia Pacific Ankylosing Spondylitis Market, by Country
7.3.1.5 Asia Pacific Others Market, by Country
7.3.2 Asia Pacific Arthritic Therapeutic Market, by Product Type
7.3.2.1 Asia Pacific Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
7.3.2.2 Asia Pacific Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
7.3.2.3 Asia Pacific Biologics Market, by Country
7.3.2.4 Asia Pacific Others Market, by Country
7.3.3 Asia Pacific Arthritic Therapeutic Market, by Country
7.3.3.1 China Arthritic Therapeutic Market
7.3.3.1.1 China Arthritic Therapeutic Market, by Application
7.3.3.1.2 China Arthritic Therapeutic Market, by Product Type
7.3.3.2 Japan Arthritic Therapeutic Market
7.3.3.2.1 Japan Arthritic Therapeutic Market, by Application
7.3.3.2.2 Japan Arthritic Therapeutic Market, by Product Type
7.3.3.3 India Arthritic Therapeutic Market
7.3.3.3.1 India Arthritic Therapeutic Market, by Application
7.3.3.3.2 India Arthritic Therapeutic Market, by Product Type
7.3.3.4 South Korea Arthritic Therapeutic Market
7.3.3.4.1 South Korea Arthritic Therapeutic Market, by Application
7.3.3.4.2 South Korea Arthritic Therapeutic Market, by Product Type
7.3.3.5 Singapore Arthritic Therapeutic Market
7.3.3.5.1 Singapore Arthritic Therapeutic Market, by Application
7.3.3.5.2 Singapore Arthritic Therapeutic Market, by Product Type
7.3.3.6 Malaysia Arthritic Therapeutic Market
7.3.3.6.1 Malaysia Arthritic Therapeutic Market, by Application
7.3.3.6.2 Malaysia Arthritic Therapeutic Market, by Product Type
7.3.3.7 Rest of Asia Pacific Arthritic Therapeutic Market
7.3.3.7.1 Rest of Asia Pacific Arthritic Therapeutic Market, by Application
7.3.3.7.2 Rest of Asia Pacific Arthritic Therapeutic Market, by Product Type
7.4 LAMEA Arthritic Therapeutic Market
7.4.1 LAMEA Arthritic Therapeutic Market, by Application
7.4.1.1 LAMEA Rheumatoid Arthritis Market, by Country
7.4.1.2 LAMEA Psoriatic Arthritis Market, by Country
7.4.1.3 LAMEA Osteoarthritis Market, by Country
7.4.1.4 LAMEA Ankylosing Spondylitis Market, by Country
7.4.1.5 LAMEA Others Market, by Country
7.4.2 LAMEA Arthritic Therapeutic Market, by Product Type
7.4.2.1 LAMEA Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
7.4.2.2 LAMEA Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
7.4.2.3 LAMEA Biologics Market, by Country
7.4.2.4 LAMEA Others Market, by Country
7.4.3 LAMEA Arthritic Therapeutic Market, by Country
7.4.3.1 Brazil Arthritic Therapeutic Market
7.4.3.1.1 Brazil Arthritic Therapeutic Market, by Application
7.4.3.1.2 Brazil Arthritic Therapeutic Market, by Product Type
7.4.3.2 Argentina Arthritic Therapeutic Market
7.4.3.2.1 Argentina Arthritic Therapeutic Market, by Application
7.4.3.2.2 Argentina Arthritic Therapeutic Market, by Product Type
7.4.3.3 UAE Arthritic Therapeutic Market
7.4.3.3.1 UAE Arthritic Therapeutic Market, by Application
7.4.3.3.2 UAE Arthritic Therapeutic Market, by Product Type
7.4.3.4 Saudi Arabia Arthritic Therapeutic Market
7.4.3.4.1 Saudi Arabia Arthritic Therapeutic Market, by Application
7.4.3.4.2 Saudi Arabia Arthritic Therapeutic Market, by Product Type
7.4.3.5 South Africa Arthritic Therapeutic Market
7.4.3.5.1 South Africa Arthritic Therapeutic Market, by Application
7.4.3.5.2 South Africa Arthritic Therapeutic Market, by Product Type
7.4.3.6 Nigeria Arthritic Therapeutic Market
7.4.3.6.1 Nigeria Arthritic Therapeutic Market, by Application
7.4.3.6.2 Nigeria Arthritic Therapeutic Market, by Product Type
7.4.3.7 Rest of LAMEA Arthritic Therapeutic Market
7.4.3.7.1 Rest of LAMEA Arthritic Therapeutic Market, by Application
7.4.3.7.2 Rest of LAMEA Arthritic Therapeutic Market, by Product Type
Chapter 8. Company Profiles
8.1 AbbVie, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Amgen, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.3.6 SWOT Analysis
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.4.6 SWOT Analysis
8.5 F. Hoffmann-La Roche Ltd.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Viatris, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Trials and Approvals:
8.6.6 SWOT Analysis
8.7 Bausch Health Companies, Inc
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Sanofi S.A.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.6 SWOT Analysis
8.10. Bristol-Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis
Chapter 9. Winning Imperatives of Arthritic Therapeutic Market

Companies Mentioned

  • AbbVie, Inc.
  • Pfizer, Inc.
  • Amgen, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Viatris, Inc.
  • Bausch Health Companies, Inc.
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company

Methodology

Loading
LOADING...